{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2509656558099983,"score_gpt":0.5050140510855577,"score_spread":0.2540483952755594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}